Ram Selvaraju Reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution and AUVELITY Upside Potential
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Ram Selvaraju reaffirmed a Buy rating on Axsome Technologies (AXSM) with a $290 price target, citing solid Q2 execution, raised 2026 guidance, and strong cash position. He highlights AUVELITY's potential in Alzheimer’s agitation as a key upside driver. Piper Sandler also reiterated a Buy with a $258 target.
H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AXSM stock, giving a Buy rating on August 18.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ram Selvaraju has given his Buy rating due to a combination of factors related to Axsome’s operating performance and growth outlook. He notes that second-quarter revenue modestly exceeded expectations, management slightly raised full-year 2026 sales guidance, and the company holds sufficient cash and access to debt to fund operations until anticipated profitability in the first half of 2027, supporting confidence in the business trajectory.
He also emphasizes that the recent share price weakness creates a favorable entry point, as current results do not yet capture the potential from AUVELITY’s launch in Alzheimer’s disease–related agitation. In his view, AUVELITY’s differentiated safety and tolerability profile versus Rexulti, strong early prescription trends—especially among older patients—and broad payer coverage underpin meaningful upside, justifying the reaffirmed $290 price target and Buy recommendation.
Selvaraju covers the Healthcare sector, focusing on stocks such as CervoMed, Urogen Pharma, and Brainsway. According to TipRanks, Selvaraju has an average return of 25.1% and a 59.00% success rate on recommended stocks.
In another report released on August 18, Piper Sandler also reiterated a Buy rating on the stock with a $258.00 price target.